NASDAQ:EGLT - Egalet Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.38 -0.02 (-5.00 %) (As of 07/16/2018 04:00 PM ET)Previous Close$0.40Today's Range$0.38 - $0.4352-Week Range$0.37 - $1.59Volume164,900 shsAverage Volume737,163 shsMarket Capitalization$21.18 millionP/E Ratio-0.16Dividend YieldN/ABeta0.58 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania. Receive EGLT News and Ratings via Email Sign-up to receive the latest news and ratings for EGLT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:EGLT CUSIPN/A Webwww.egalet.com Phone610-833-4200 Debt Debt-to-Equity Ratio-3.00 Current Ratio2.29 Quick Ratio2.24 Price-To-Earnings Trailing P/E Ratio-0.16 Forward P/E Ratio-0.40 P/E GrowthN/A Sales & Book Value Annual Sales$26.14 million Price / Sales0.77 Cash FlowN/A Price / CashN/A Book Value($0.86) per share Price / Book-0.44 Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-69,350,000.00 Net Margins-208.90% Return on EquityN/A Return on Assets-57.93% Miscellaneous Employees131 Outstanding Shares52,700,000Market Cap$21.18 Egalet (NASDAQ:EGLT) Frequently Asked Questions What is Egalet's stock symbol? Egalet trades on the NASDAQ under the ticker symbol "EGLT." How were Egalet's earnings last quarter? Egalet (NASDAQ:EGLT) posted its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.03. The specialty pharmaceutical company had revenue of $6.26 million for the quarter, compared to analysts' expectations of $8.10 million. View Egalet's Earnings History. When is Egalet's next earnings date? Egalet is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Egalet. What price target have analysts set for EGLT? 4 Wall Street analysts have issued twelve-month price objectives for Egalet's shares. Their predictions range from $1.50 to $7.00. On average, they anticipate Egalet's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 821.1% from the stock's current price. View Analyst Ratings for Egalet. What is the consensus analysts' recommendation for Egalet? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Egalet in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Egalet's key competitors? Some companies that are related to Egalet include Sunesis Pharmaceuticals (SNSS), Elite Pharmaceuticals, Inc. Common Stock (ELTP), Medicure Inc. Common Stock (MCUJF), VIVUS (VVUS), Cardiome Pharma (CRME), Axsome Therapeutics (AXSM), GT Biopharma (GTBP), Vernalis (VNLPY), KemPharm (KMPH), Novan (NOVN), Trillium Therapeutics (TRIL), Pharmaxis Limited ADR Common Stock (PXSLY), Aileron Therapeutics (ALRN), Versartis (VSAR) and Merrimack Pharmaceuticals (MACK). Who are Egalet's key executives? Egalet's management team includes the folowing people: Mr. Robert S. Radie, Pres, CEO & Director (Age 55)Mr. Stanley J. Musial, Exec. VP, CFO & Sec. (Age 57)Dr. Mark Strobeck, Exec. VP & COO (Age 47)Ms. Barbara A. Carlin, Sr. VP & Chief Accounting Officer (Age 43)Dr. Karsten Lindhardt M.Sc., Ph.D., Chief Scientific Officer (Age 46) Has Egalet been receiving favorable news coverage? News headlines about EGLT stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Egalet earned a daily sentiment score of 0.15 on Accern's scale. They also gave news headlines about the specialty pharmaceutical company an impact score of 46.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. How do I buy shares of Egalet? Shares of EGLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Egalet's stock price today? One share of EGLT stock can currently be purchased for approximately $0.38. How big of a company is Egalet? Egalet has a market capitalization of $21.18 million and generates $26.14 million in revenue each year. The specialty pharmaceutical company earns $-69,350,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Egalet employs 131 workers across the globe. How can I contact Egalet? Egalet's mailing address is 600 LEE ROAD SUITE 100, WAYNE PA, 19087. The specialty pharmaceutical company can be reached via phone at 610-833-4200 or via email at [email protected] MarketBeat Community Rating for Egalet (NASDAQ EGLT)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 291 (Vote Outperform)Underperform Votes: 164 (Vote Underperform)Total Votes: 455MarketBeat's community ratings are surveys of what our community members think about Egalet and other stocks. Vote "Outperform" if you believe EGLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGLT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?